Moreover, genetic deletion or pharmacological inhibition of S100A8/A9 can inhibit the TLR4/NLRP3/IL-1β pathway, suppressing ischemia-induced granulopoiesis and improving cardiac dysfunction [16]. The gene discussed is TLR4; the disease is ischemia.